Lot certificates

You’ll see American Peptides on the lab’s copy. They’re our supplier.

• 5 mg / 5 mg, lot CJCIP10-0803: 99.80% purity (RP-HPLC), 5.13 mg / 5.55 mg measured, identity confirmed by mass spec. Issued 2026-08-28 by Bioviridian Inc.. Verify certificate COA7607
• 10 mg / 10 mg, lot CJCIP20-0803: 99.82% purity (RP-HPLC), 10.62 mg / 10.55 mg measured, identity confirmed by mass spec. Issued 2026-08-28 by Bioviridian Inc.. Verify certificate COA7631

Our vials are filled from lots made by our supplier, American Peptides, and tested by Bioviridian Inc.The laboratory’s original certificate lists American Peptides as the vendor. Look up the code at bioviridians.com to check it.

What researchers study it for

• Chemistry relative to GHRH(1-29)
• Identification in confiscated doping samples
• Selectivity for growth hormone over other pituitary hormones
• Animal work on which pituitary hormones respond

How it is thought to work

CJC-1295 (no DAC): Because it is built on GHRH(1-29), the assumption is that it engages the GHRH receptor on somatotroph cells in the pituitary. Ipamorelin: It binds the ghrelin receptor (GHS-R1a), and the pituitary responds by letting out growth hormone.

Where the research stands

Blend of research compounds. Each component is studied separately; as a combined vial it has no dedicated published research. The least-established component is CJC-1295 (no DAC): nothing published in humans.

Sources

1. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.. Endocrinology.
2. Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M (2026). The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.. Front Endocrinol (Lausanne).
3. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH (1998). Ipamorelin, the first selective growth hormone secretagogue.. Eur J Endocrinol.
4. Gobburu JV, Agersø H, Jusko WJ, Ynddal L (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.. Pharm Res.